云顶新耀医药科技有限公司 Mediaroom

Everest Medicines Enters into Letter of Intent with Hasten Biopharmaceuticals (Asia) Limited

SHANGHAI, March 18, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2026-03-18 11:07 4334

Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026 and Hold Online Earnings Call

SHANGHAI, March 16, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2026-03-16 17:58 2063

Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

* VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, ...

2026-03-13 18:05 3321

Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026

SHANGHAI, March 10, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2026-03-10 18:40 2681

Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY® in Mainland China

SHANGHAI, March 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2026-03-09 21:27 5535

Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis

SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2026-02-06 13:10 6323

Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013

SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"...

2026-02-05 08:17 5517

Everest Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"...

2026-01-06 07:58 9528

Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol

SHANGHAI, Dec. 17, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2025-12-17 16:10 3394

Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder

SHANGHAI, Dec. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2025-12-15 12:40 3444

Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten

- Accretive Commercialization Services Agreement covering six mature assets across critical care, c...

2025-12-11 23:57 3648

Everest Medicines Announces First Patient Dosed in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14

* The first patient had received the first dose of EVM14 injection in a global, multi-center Phas...

2025-11-21 12:01 2675

Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

* Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-...

2025-10-30 11:05 1886

Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14

SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2025-10-14 12:13 1507

Everest Medicines Announces NMPA Approval of IND Application for Tumor-Associated Antigen Cancer Vaccine EVM14

* EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receiv...

2025-10-13 08:47 1559

Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology

* The published study results are from the ENLIGHT UC study (ES101002), a multicenter, randomized...

2025-10-09 13:10 1567

Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC

Shanghai, Aug. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2025-08-15 09:35 2292

Latest News